Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glutamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | GRM8 | O00222 | 2/20 | 0.72 |
| ▸ | GRM6 | O15303 | 2/20 | 0.72 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.72 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.72 |
| ▸ | GSR | P00390 | 2/20 | 0.72 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.72 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.72 |
| ▸ | GRM5 | P41594 | 1/20 | 0.72 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.72 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.72 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.72 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.72 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.72 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.72 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.72 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.72 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL1963374 | 1.00 | CYP1A2 (0.72) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL9679290 | 1.00 | CYP1A2 (0.72) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL9679295 | 1.00 | CYP1A2 (0.72) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL1444866 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL4531318 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL29406755 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL1444865 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL8637356 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL4531315 | 0.94 | CYP1A2 (0.82) | CYP1A2GRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL8843182 | 0.93 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRM7GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023040793-A1 | ANTI-INFLAMMATORY COMPOUND AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-03-23 | — | — | WO | claimed |
| CN-118201943-A | Anti-inflammatory compound and application thereof | 映恩生物制药（苏州）有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117607606-A | Power system transient state calculation method considering short circuit ratio of new energy multi-station | 国网吉林省电力有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023040793-A1 | ANTI-INFLAMMATORY COMPOUND AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-03-23 | — | — | WO | disclosed |
| WO-2011072264-A2 | METHODS AND COMPOSITIONS FOR BIOMASS TREATMENT | QTEROS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| US-6599940-B2 | Neurotransmitters | GEORGETOWN UNIVERSITY | 2003-07-29 | — | — | US | disclosed |
| US-20020147362-A1 | Synthesis of 2-Hydroxymethylglutamic acid and congeners thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002022622-A2 | SYNTHESIS OF 2-HYDROXYMETHYLGLUTAMIC ACID AND CONGENERS THEREOF | GEORGETOWN UNIVERSITY (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147362-A1 | Synthesis of 2-Hydroxymethylglutamic acid and congeners thereof | OGDH, FPGS, GGCT | CYP1A2 330/4885GRM8 1359/4885GRM6 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.